ANALGESIC, ANESTHETIC, AND ADDICTION CLINICAL TRIAL TRANSLATIONS, INNOVATIONS, OPPORTUNITIES, AND NETWORKS (ACTTION) Public-Private Partnership WITH.

Slides:



Advertisements
Similar presentations
Current and Future Challenges in Designing Behavioral Interventions: From Randomized Trials to Community Implementation Current and Future Challenges in.
Advertisements

Relieving Pain in America A Blueprint for Transforming Prevention, Care, Education, and Research IOM Committee on Advancing Pain Research, Care, and Education.
Health Line of Business Revised Health Domains January 26, 2005 Outcomes / Domains have been revised.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
Definition of Clinical Research in Rehabilitation What is involved? What is studied? Where is it done? Patient oriented research  patient interaction.
1. 2 Implementing and Evaluating of an Evidence Based Nursing into Practice Prepared By Dr. Nahed Said El nagger Assistant Professor of Nursing H.
Cancer Nanotechnology: New Opportunities for Targeted Therapies FDA Public Meeting October 10, 2006 Piotr Grodzinski, Ph.D. Director, Nanotechnology for.
Veterinary Specialties. A Diplomate of the American Veterinary Dental College (AVDC) is a veterinarian who has been certified by AVDC as having demonstrated.
The NIH Roadmap for Medical Research
ANALGESIC CLINICAL TRIAL INNOVATIONS, OPPORTUNITIES, AND NETWORKS (ACTION) ACTION Inaugural Workshop
Veterinary Specialties. Currently, there are 21 AVMA-recognized veterinary specialty organizations comprising 40 distinct specialties. More than 10,200.
Specific Clinical/Regulatory Issues in Development of Drugs for Peripheral Neuropathy and Neuropathic Pain Gerald J. Dal Pan, MD, MHS Medical Officer Division.
Analgesic clinical trials and their assay sensitivity Robert H. Dworkin, PhD Professor of Anesthesiology, Neurology, Oncology, and Psychiatry Professor,
Organization of the US Health Services System
1 The ACTION Public-Private Partnership: Background, Rationale, and Objectives Bob A. Rappaport, M.D. Director Division of Anesthesia, Analgesia, and Addiction.
Introduction to Basic Science Emily L. Lowe, Ph.D. Microbiology, Immunology and Molecular Genetics UCLA.
Bernard A Fox, PhD Immediate Past President and Chair, Executive Council Society for Immunotherapy of Cancer (SITC) Defining the Critical Hurdles in Cancer.
Stefan Franzén Introduction to clinical trials.
Analgesic Drug Development for Neuropathic Pain Methodologic Issues Najib Babul, PharmD TheraQuest Biosciences
Partnering with Federal Labs: A Panel Discussion FLC Mid-Atlantic Region Annual Meeting October 24, 2007.
Experimental Cancer Medicine – the future of cancer care Rosie Davies (LECMC RP based at RLUH) Janet Davies (LECMC RP based at CCO)
Innovation Through Collaboration: Why the CSS Working Groups are Important to the FDA Steve Wilson, DrPH, CAPT USPHS Director, FDA/CDER/OTS/OB/DBIII 2014.
ACTION Going Forward: A Proposed Strategic Plan Dennis C. Turk, Ph.D. Associate Director, ACTION University of Washington.
A Model for Translating Research into Practice in the United States - Mexico Border Region Howard J. Eng, MS, DrPH Director, Southwest Border Rural Health.
Activities at Academic Research Centers: Identifying Present Activities and Future Opportunities ICORD V February 24, 2009 Jim Cloyd, PharmD Lawrence Weaver.
The “Centers for Education & Research on Therapeutics” (CERTs) Funding Opportunity Announcements FOAs RFA-HS and RFA-HS Technical Assistance.
NAS/IOM Review of Rare Diseases Research and Orphan Products Development - USA Timothy Cote, M.D., MPH Director, Office of Orphan Products Development.
The Importance of a Strategic Plan to Eliminate Health Disparities 2008 eHealth Conference June 9, 2008 Yvonne T. Maddox, PhD Deputy Director Eunice Kennedy.
Initiating phase 1 clinical trials in pediatric oncology National Cancer Institute Perspective Barry Anderson, MD, PhD Pediatric Section Cancer Therapy.
Mark Clanton, M.D. M.P.H. Deputy Director Cancer Care Delivery Systems Moving Discovery Through to Delivery: A Critical Opportunity for Leadership and.
Component 1: Introduction to Health Care and Public Health in the U.S. 1.1: Unit 2: Health Care Settings 1.2 a: Overview and the Organization of Federal.
Comparative Effectiveness Research : Rethinking Therapeutic Evaluation in Chronic Diseases Ph Ravaud.
Agency for Healthcare Research and Quality Advancing Excellence in Health Care The “Centers for Education & Research on Therapeutics” (CERTs)
Why Write A Grant? Elaine M. Hylek, MD, MPH Professor of Medicine Associate Director, Education and Training Division BU CTSI Section of General Internal.
General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,
Opiate Analgesic Use in Pediatric Patients Bob Rappaport, M.D. Deputy Division Director Division of Anesthetic, Critical Care and Addiction Drug Products,
Mt. Hood. IOM Report: 10 Years After & More Coming Mitch Greenlick, Ph.D. Oregon State Representative April 21, 2010.
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD Barriers to Pharmaceutical Innovation Richard Laing EDM/PAR WHO.
Component 1: Introduction to Health Care and Public Health in the U.S. 1.9: Unit 9: The evolution and reform of healthcare in the US 1.9c: Quality Indicators.
Methodological Issues in Implantable Medical Device(IMDs) Studies Abdallah ABOUIHIA Senior Statistician, Medtronic.
1 Trends in drug development programs in the era of Personalized Medicine Gunnar Saeter, M.D., Ph.D. Head, Institute for Cancer Research Oslo University.
Explore Your Interests APTA Section Membership. Benefits of Section Membership Networking and Communities Publications Certification Resources Leadership.
Chapter 22 REGULATORY AND ADVISORY AGENCIES. Introduction 2.
Analgesic Drug Development for Chronic Pain A Brief to the FDA Arthritis Advisory Committee July 29, 2002 Najib Babul, PharmD.
CLINICAL TRIALS.
CLI and Device Intervention Across the Pacific – An FDA View
Building a Drug Repurposing Network (DR3N) for the CTSA Consortium:
The Health Services Research Centre and NAP5
A stroke is the leading cause of permanent impairment and disability
An introduction to personalised medicine & health in Leeds
Presentation Developed for the Academy of Managed Care Pharmacy
FDA Perspective on Cardiovascular Device Development
GARD/NCD Action Plan & 2011 UN Summit on NCDs
Action: BM0806 Recent Advances in Histamine Receptor H4R Research
Is a Clinical Trial Right for Me?
Innovative Medicines Initiative:
Professional Organizations
Strategy and Policy Cohesion: “The One Health Agenda: will it deliver”
Phase 2 to phase 3 clinical trial transitions: Reasons for success and failure in immunologic diseases  Dhavalkumar D. Patel, MD, PhD, Christian Antoni,
Defining the Clinical Value of Endpoints Used in Migraine Trials
National Cancer Center
Trial Funding and Engagement: The NIH Sponsored CTSA Program
Pediatric Clinical investigator training workshop
Opening an IND: Investigator Perspective
Public/Population Health Approach to Substance Abuse Prevention & Treatment Determine the Burden of Substance Abuse and Service Barriers to Develop Plan.
An introduction to EMA’s support for medicines development
Introduction, Meeting Objectives and roadmap
Building PHN Scientists
Centers of Excellence for Childhood Obesity
Center for Clinical and Translational Science
Presentation transcript:

ANALGESIC, ANESTHETIC, AND ADDICTION CLINICAL TRIAL TRANSLATIONS, INNOVATIONS, OPPORTUNITIES, AND NETWORKS (ACTTION) Public-Private Partnership WITH THE FDA Robert H. Dworkin, PhD Professor of Anesthesiology, Neurology, and Psychiatry Professor in the Center for Human Experimental Therapeutics University of Rochester School of Medicine and Dentistry

“The science base necessary to evaluate and predict safety and efficacy … is different from the science that generates the new idea for a drug, biologic or device. In general, the National Institutes of Health and academia do not perform research in this area, indicating the need to develop mechanisms and incentives to foster research directed at improving the scientific base for the critical path, for example, for analgesic drug development.” Woodcock J, et al. Nature Reviews Drug Discovery 2007;6:703-710

Mission of ACTTION To identify, prioritize, sponsor, coordinate, and promote innovative activities — with a special interest in optimizing clinical trials — that will expedite the discovery and development of improved analgesic, anesthetic, addiction, and peripheral neuropathy treatments for the benefit of the public health.

Consortia and Collaborations Consortium for Addiction Research on Efficacy and Safety (CARES) Consortium on Clinical Endpoints and Procedures for Peripheral Neuropathy Trials (CONCEPPT) Sedation Consortium on Endpoints and Procedures for Treatment, Education, and Research (SCEPTER) Collaborations ACTTION-American Pain Society Pain Taxonomy (AAPT) — Chronic Pain ACTTION-American Pain Society-American Academy of Pain Medicine Pain Taxonomy (AAAPT) — Acute Pain

Working Groups Abuse Liability Evaluation for Research , Treatment, and Training (ALERTT) Analgesic Comparative Effectiveness and Pragmatic Trials (ACEPT) Community Patient Awareness About Clinical Trials (COMPAACT) Pain-Related Outcomes Training and Evaluation for Conducting Clinical Trials (PROTECCT) Public Relations and Other Communication and Education Strategies (PROCESS) Repository of Registered Analgesic Clinical Trials (RReACT) Resource for Evaluating Procedures and Outcomes of Randomized Trials (REPORT) Retrospective Evaluation of Patient-Level Information from Controlled Analgesic Trials of Efficacy (REPLICATE) Safety and Benefit-Risk Reporting and Evaluation (SABRRE) Standardized Analgesic Database for Research, Discovery, and Submissions (STANDARDS)

Major Research Objective Develop an evidence-based approach to the design, execution, analysis, and interpretation of clinical trials of analgesic, addiction, sedation, and peripheral neuropathy clinical trials

Partners – Professional & Research Societies American Academy of Neurology American Academy of Pain Medicine American College of Rheumatology American Pain Society American Society of Anesthesiologists Europain German Research Network on Neuropathic Pain International Association for the Study of Pain Osteoarthritis Research Society International Outcome Measures in Rheumatology

Partners – US Government Agencies Food and Drug Administration Department of Veteran Affairs National Institutes of Health Department of Defense

Industry Partners – CONCEPPT

CONCEPPT Publication (others in the pipeline)

www.acttion.org

ANALGESIC, ANESTHETIC, AND ADDICTION CLINICAL TRIAL TRANSLATIONS, INNOVATIONS, OPPORTUNITIES, AND NETWORKS (ACTTION) Public-Private Partnership WITH THE FDA

INTRODUCTION

Background Consequence of success Number of cancer survivors Change of focus - quality of survival CIPN Substantial prevalence, disability, reduced QOL even years after treatment Dose reduction or discontinuation of chemotherapy with possible effects on survival

Background Challenges Goals 1. to evaluate disease modification of CIPN 2. to evaluate symptomatic treatment of CIPN 3. to evaluate chemotherapy disruption due to CIPN 4. to define a research agenda for the unknowns